Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma - Concepedia

Concepedia

Publication | Open Access

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma

DOI Full Paper Access

101

Citations

39

References

2023

Year

Martin Kaiser, Andrew Hall, Katrina Walker, Amy L. Sherborne, Ruth M. de Tute, Nicola Newnham, Sadie Roberts, Emma Ingleson, Kristian M. Bowles, Mamta Garg,

Journal of Clinical Oncology

Abstract

Our results suggest that Dara-CVRd induction and extended post-ASCT Dara-VRd consolidation markedly improve PFS for UHiR NDMM patients over conventional management, supporting further evaluation of this strategy.

References

	Year	Citations

Page 1